NX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune responses
Wednesday, November 1, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix is focused on developing innovative therapies for cancer and autoimmune diseases. Their approach involves leveraging novel scientific insights to enhance treatment efficacy. The article highlights their commitment to advancing a diverse portfolio of assets, including NX-1607, a small molecule inhibitor aimed at improving anti-PD-1-mediated tumor growth inhibition.
Price reaction · baseline $5.59 (2023-10-31 close) · hit pre-market · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
+1.3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.